Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of lncRNA to preparation of products for diagnosing and/or treating osteoarthritis

A technology for osteoarthritis and products, applied in the field of biomedicine, can solve the problems of limited treatment methods, treatment methods are limited to patients with advanced osteoarthritis, and late detection of osteoarthritis

Active Publication Date: 2020-05-15
XIAN HONGHUI HOSPITAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there is still no satisfactory method for the treatment of osteoarthritis. Although some patients do not find symptoms similar to osteoarthritis, the X-ray of radiological detection technology shows that there is a trend of osteoarthritis. The difference between the appearance of such symptoms and the actual detection Time interval results in late detection of osteoarthritis and therefore limited treatment options
At present, joint replacement surgery is widely used, but the existing treatment methods are limited to patients with advanced osteoarthritis (Vonk, L.A., et al., Overexpression of hsa-miR-148a promotes cartilage production and inhibitscartilage degradation by osteoarthritic chondrocytes.Osteoarthritis and Cartilage, 2014.22(1):145-153.)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lncRNA to preparation of products for diagnosing and/or treating osteoarthritis
  • Application of lncRNA to preparation of products for diagnosing and/or treating osteoarthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Example 1 QPCR sequencing to verify the expression of RP11-159F24.3 gene

[0064] 1. Sample collection

[0065] A total of 78 patients undergoing knee replacement surgery were selected, including 48 OA patients and 30 normal controls. Blood samples and tissue samples were collected from the patients. The age and gender of the OA group and the control group were not statistically significant.

[0066] OA group: Inclusion criteria: 1) Osteoarthritis patients diagnosed according to OA diagnostic criteria, underwent knee replacement surgery; 2) Initial replacement. Exclusion criteria: 1) Patients with other inflammatory arthritis or autoimmune diseases, including rheumatoid arthritis, gout, systemic lupus erythematosus, etc.; 2) Patients with a history of severe trauma to the knee joint; 3) Patients with steroids within the past 3 months Those with a history of drug injection or application of non-steroidal drugs; 4) those with severe liver and kidney function diseases and...

Embodiment 2

[0077] Example 2 Silencing of RP11-159F24.3 gene and its influence on cells

[0078] 1. Cell acquisition and culture

[0079] Repeatedly wash the bone tissue of soft OA patients with PBS containing 1% double antibody for 3 times, and cut the tissue to 1mm with sterile small ophthalmic scissors 3 Put the cartilage fragments into 10cm Petri dish, add 10ml of fresh 0.25% trypsin, 37℃, 5%CO 2 Digest in the incubator for 30min to remove possible attached fibroblasts. Aspirate the trypsin digestion solution, add 10ml of DMEM culture solution containing 10% FBS, pipette and mix well to stop the digestion, wash twice with 10ml of PBS containing double antibody. Add 10ml of 0.2% type II collagenase to the petri dish, place at 37°C, 5% CO 2 Digest for 4 hours in the incubator. The dissociated chondrocyte suspension containing collagenase solution was sucked out with a pipette, filtered through a 70 μm 200-mesh cell sieve, the obtained filtrate was transferred to a centrifuge tube an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of lncRNA to preparation of products for diagnosing and / or treating osteoarthritis, specifically provides an application of lncRNA RP11-159F24.3 to preparation ofproducts for diagnosing and / or treating osteoarthritis, and further provides an application of the lncRNA RP11-159F24.3 to candidate medicines for screening and treating the osteoarthritis.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the application of lncRNA in the preparation of products for diagnosing and / or treating osteoarthritis. Background technique [0002] Osteoarthritis (OA) is the most common form of arthritis and the most common chronic joint disease in the world, affecting approximately 10% of the population, especially women over the age of 60 (Dai, J., et al., Kdm6b regulates cartilage development and homeostasis through anabolic metabolism. Annals of the Rheumatic Diseases, 2017.76(7):1295-1303.), the prevalence rate gradually increases with age, which seriously threatens human health. About 26% of patients with osteoarthritis have severe joint pain, and about 42% of them have greatly limited their physical activities (Wang, A., et al., Nutraceuticals and osteoarthritis pain. Pharmacology & Therapeutics, 2018.187 :167-179.). Osteoarthritis is the main cause of inflammation and changes in joint struct...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6883A61K45/00A61K48/00A61K31/713A61P19/02
CPCA61K31/713A61K45/00A61P19/02C12Q1/6883C12Q2600/178
Inventor 宋伟王军马涛程辉光张育民
Owner XIAN HONGHUI HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com